🔴 Cerenome is trading 22.22% down; no clear company-specific catalyst identified

Cerenome is trading at $1.33, down 22.22%, with no clear company-specific catalyst identified for the November 3 decline.

• Its latest reported major update was October 29, when it completed enrollment in its Phase 2 ReSPECT-GBM trial; topline data are expected in mid-2027. That update does not establish a reason for the decline.
• The supplied market context is mixed: the S&P 500 and Nasdaq are higher, so it does not clearly explain the decline.